Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic
Executive Summary
Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product
You may also be interested in...
Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II
Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased
Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II
Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased
Sanofi’s Lovenox Weathers Heparin Storm; Pipeline Faces Some Setbacks
Sanofi-Aventis' antithromboticLovenox is currently enjoying a bump from the fallout of the heparin scandal, with increased sales in the U.S. where the low molecular weight heparin is produced domestically. But it may be short-lived, as Momenta and Sandoz are gearing up to re-submit their ANDA for enoxaparin